Corinne Castelnau
Overview
Explore the profile of Corinne Castelnau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
707
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loureiro D, Tout I, Narguet S, Bed C, Roinard M, Sleiman A, et al.
Hepatology
. 2022 Aug;
77(4):1348-1365.
PMID: 35971873
Background And Aims: Hepatitis B virus (HBV) infection causes oxidative stress (OS) and alters mitochondria in experimental models. Our goal was to investigate whether HBV might alter liver mitochondria also...
2.
Loureiro D, Castelnau C, Tout I, Boyer N, Narguet S, Menasria Benazzouz S, et al.
Liver Int
. 2021 Jun;
41 Suppl 1:30-37.
PMID: 34155804
Hepatitis delta virus (HDV) infection is a defective virus requiring hepatitis B virus (HBV) for its complete replication cycle. HDV is a small hepatotropic RNA virus and around 15 to...
3.
Asselah T, Loureiro D, Le Gal F, Narguet S, Brichler S, Bouton V, et al.
Liver Int
. 2021 May;
41(7):1509-1517.
PMID: 33999515
Hepatitis delta virus (HDV) infection is the most severe form of viral hepatitis. Bulevirtide (BLV, Hepcludex ) is an HDV/HBV entry inhibitor approved in June 2020 in the European Union...
4.
Roulot D, Brichler S, Layese R, BenAbdesselam Z, Zoulim F, Thibault V, et al.
J Hepatol
. 2020 Jul;
73(5):1046-1062.
PMID: 32634548
Background & Aims: HDV infection causes severe chronic liver disease in individuals infected with HBV. However, the factors associated with poor prognosis are largely unknown. Thus, we aimed to identify...
5.
Asselah T, Loureiro D, Tout I, Castelnau C, Boyer N, Marcellin P, et al.
Liver Int
. 2020 Feb;
40 Suppl 1:54-60.
PMID: 32077603
Around 15-20 million people develop chronic hepatitis delta virus worldwide. Hepatitis delta virus (HDV) is a defective RNA virus requiring the presence of the hepatitis B virus surface antigen (HBsAg)...
6.
Kutala B, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, et al.
Hepat Med
. 2018 Jan;
9:67-73.
PMID: 29296102
Background: The combination of sofosbuvir (SOF) with ribavirin (RBV) or daclatasvir (DCV) or simeprevir (SIM) for the treatment of patients infected by chronic hepatitis C (CHC) have led to significantly...
7.
Stern C, Martinot-Peignoux M, Ripault M, Boyer N, Castelnau C, Valla D, et al.
World J Gastroenterol
. 2012 Jun;
18(23):2966-72.
PMID: 22736920
Aim: To study the efficacy and factors associated with a sustained virological response (SVR) in chronic hepatitis C (CHC) relapsing patients. Methods: Out of 1228 CHC patients treated with pegylated...
8.
Cardoso A, Carvalho-Filho R, Stern C, Dipumpo A, Giuily N, Ripault M, et al.
Liver Int
. 2011 Nov;
32(4):612-21.
PMID: 22103765
Background/aims: Accuracy of transient elastography (TE) in hepatitis B virus (HBV) infection has not been well established. We aimed to compare the performances of TE for the assessment of liver...
9.
Ozenne V, Bouattour M, Goutte N, Vullierme M, Ripault M, Castelnau C, et al.
Dig Liver Dis
. 2011 Jul;
43(12):1001-5.
PMID: 21798829
Background: An increasing proportion of patients with hepatocellular carcinoma are older than 75 years. Previous studies suggested that ageing does not adversely impact survival but they have the drawback of...
10.
Cardoso A, Moucari R, Figueiredo-Mendes C, Ripault M, Giuily N, Castelnau C, et al.
J Hepatol
. 2010 Mar;
52(5):652-7.
PMID: 20346533
Background & Aims: Hepatocellular carcinoma (HCC) currently represents the major cause of liver-related death in patients with hepatitis C virus (HCV)-related cirrhosis. We assessed the influence of combination therapy on...